Radiosensitivity in Fanconi anaemia: application to the conditioning regimen for bone marrow transplantation.

Umbilical cord blood transplantation: the first 25 years and beyond. Blood (2013) 2.79

Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood (2006) 1.82

Fanconi anaemia. J Med Genet (2003) 1.70

SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood (2013) 1.68

Alternative donor hematopoietic cell transplantation for Fanconi anemia. Blood (2015) 1.49

GS-nitroxide (JP4-039)-mediated radioprotection of human Fanconi anemia cell lines. Radiat Res (2011) 0.99

Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia. Mutat Res (2009) 0.96

Stem cells - biological update and cell therapy progress. Clujul Med (2015) 0.91

BRCA1, FANCD2 and Chk1 are potential molecular targets for the modulation of a radiation-induced DNA damage response in bystander cells. Cancer Lett (2014) 0.89

The hematopoietic system in the context of regenerative medicine. Methods (2015) 0.84

Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation (HCT) for Inherited Bone Marrow Failure Syndromes (IBMFS): Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant (2017) 0.75

Transplantation for congenital bone marrow failure syndromes. Bone Marrow Res (2010) 0.75

Exploiting biological and physical determinants of radiotherapy toxicity to individualize treatment. Br J Radiol (2015) 0.75

Alternative donor transplant of benign primary hematologic disorders. Bone Marrow Transplant (2015) 0.75

Interleukin 8/KC enhances G-CSF induced hematopoietic stem/progenitor cell mobilization in Fancg deficient mice. Stem Cell Investig (2014) 0.75

Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia. Vaccine (2017) 0.75

Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med (1989) 5.81

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet (1998) 3.62

Haemopoietic growth factors in aplastic anaemia: a cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic Anaemia. Lancet (1994) 3.24

Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med (2000) 3.19

Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood (2001) 2.99

Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol (1997) 2.79

The expression of cytokine and cytokine receptor genes in long-term bone marrow culture in congenital and acquired bone marrow hypoplasias. Br J Haematol (1993) 2.66

Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med (1993) 2.52

Dyskeratosis Congenita (DC) Registry: identification of new features of DC. Br J Haematol (1998) 2.43

Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet (1996) 2.41

Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet (1995) 2.40

An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant (2003) 2.19

Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood (1993) 2.12

Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood (1992) 2.11

Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol (2000) 2.06

Allogeneic blood stem cell transplantation: considerations for donors. Blood (1997) 2.03

Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood (1990) 1.98

Detection of maternal cells in human fetal blood during the third trimester of pregnancy using allele-specific PCR amplification. Br J Haematol (1997) 1.95

Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur J Hum Genet (1997) 1.89

Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis. Eur J Clin Microbiol Infect Dis (1996) 1.89

Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood (1991) 1.88

KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia (2009) 1.80

Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood (1996) 1.77

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med (1988) 1.73

Fasciitis in chronic graft-versus-host disease. A clinicopathologic study of 14 cases. Ann Intern Med (1994) 1.69

Molecular typing of environmental and patient isolates of Aspergillus fumigatus from various hospital settings. J Clin Microbiol (1998) 1.68

Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol (1988) 1.66

Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood (1999) 1.63

Growth hormone deficiency caused by pituitary stalk interruption in Fanconi's anemia. J Pediatr (2001) 1.57

Brief report: correction of X-linked lymphoproliferative disease by transplantation of cord-blood stem cells. N Engl J Med (1993) 1.53

Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet (1983) 1.53

Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol (1990) 1.53

Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res (1991) 1.51

Umbilical cord blood hematopoietic stem and repopulating cells in human clinical transplantation. Blood Cells (1991) 1.50

Three cases of typical aplastic anaemia associated with a Philadelphia chromosome. Br J Haematol (2001) 1.48

Single dose versus hyperfractionated total body irradiation before allogeneic bone marrow transplantation: a non-randomized comparative study of 54 patients at the Institut Gustave-Roussy. Radiother Oncol (1989) 1.48

The umbilical cord blood alphabeta T-cell repertoire: characteristics of a polyclonal and naive but completely formed repertoire. Blood (1998) 1.48

Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol (1998) 1.47

Late vascular complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol (1991) 1.47

Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood (1989) 1.46

Toxoplasmosis in bone marrow-transplant recipients: report of seven cases and review. Clin Infect Dis (1992) 1.42

Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors. Ann Intern Med (1986) 1.42

Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. Blood (1999) 1.42

Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol (2000) 1.39

Patents versus transplants. Nature (1996) 1.38

Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions. Lancet (1977) 1.37

Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant (2006) 1.36

Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis (1999) 1.33

Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM). Br J Haematol (1997) 1.33

Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant (1994) 1.33

Risk factors for acute graft-versus-host disease. Br J Haematol (1987) 1.33

Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation. Blood (2000) 1.31

Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. II. In vitro and in vivo spontaneous overproduction of tumor necrosis factor alpha. Blood (1994) 1.30

Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis (2004) 1.30

Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1998) 1.30

Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet (1994) 1.29

Association of complementation group and mutation type with clinical outcome in fanconi anemia. European Fanconi Anemia Research Group. Blood (2000) 1.29

Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies. Bone Marrow Transplant (2007) 1.28

Late clonal diseases of treated aplastic anemia. Semin Hematol (2000) 1.27

Accelerated telomere shortening and telomerase activation in Fanconi's anaemia. Br J Haematol (1999) 1.26

Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation (2001) 1.25

Cord blood T lymphocytes lack constitutive perforin expression in contrast to adult peripheral blood T lymphocytes. Blood (1995) 1.24

An alternatively spliced form of HLA-G mRNA in human trophoblasts and evidence for the presence of HLA-G transcript in adult lymphocytes. Proc Natl Acad Sci U S A (1994) 1.23

Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle. Blood (1996) 1.23

Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet (1987) 1.22

Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol (2001) 1.21

Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients. Transplantation (1988) 1.20

High-resolution HLA typing by sequencing for HLA-A, -B, -C, -DR, -DQ in 122 unrelated cord blood/patient pair transplants hardly improves long-term clinical outcome. Bone Marrow Transplant (2005) 1.19

Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol (2001) 1.19

Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis (2000) 1.19

Late thyroid toxicity in 153 long-term survivors of allogeneic bone marrow transplantation for acute lymphoblastic leukaemia. Bone Marrow Transplant (2005) 1.17

Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood (2001) 1.16

Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood (1999) 1.16

Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol (2002) 1.15

Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia (2008) 1.14

Factors affecting lymphocyte subset reconstitution after either related or unrelated cord blood transplantation in children -- a Eurocord analysis. Br J Haematol (2001) 1.12

Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol (2000) 1.12

Myelofibrosis with myeloid metaplasia. N Engl J Med (2000) 1.11

Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant (2003) 1.11

Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle. J Clin Oncol (1997) 1.11

Clinical significance of cytomegalovirus viremia in bone marrow transplantation. Transplantation (1985) 1.11

Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia (1997) 1.10

Unrelated donor marrow transplants for severe acquired aplastic anemia. Bone Marrow Transplant (1992) 1.09

Hematopoietic stem-cell transplants using umbilical-cord blood. N Engl J Med (2001) 1.09

Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann Rheum Dis (2007) 1.09

Epidemiology and diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients: results of a 5 year retrospective study. Bone Marrow Transplant (1993) 1.08